Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of bacteroides fragilis capsular polysaccharide A and PD-1 and PD-L1 antibodies in combined treatment of respiratory system tumors

A technology of Bacteroides fragilis and PD-L1, applied in the field of biomedicine, can solve the problem of combined treatment of respiratory system tumors without Bacteroides fragilis zwitterionic capsular polysaccharides and immune checkpoint inhibitors, so as to enhance the body's anti-tumor immune response , prevent the occurrence and development, and improve the quality of life

Active Publication Date: 2022-05-10
GUANGZHOU ZHIYI PHARMA INC
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] There is currently no literature on the use of Bacteroides fragilis zwitterionic capsular polysaccharides in combination with immune checkpoint inhibitors for the treatment of respiratory tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bacteroides fragilis capsular polysaccharide A and PD-1 and PD-L1 antibodies in combined treatment of respiratory system tumors
  • Application of bacteroides fragilis capsular polysaccharide A and PD-1 and PD-L1 antibodies in combined treatment of respiratory system tumors
  • Application of bacteroides fragilis capsular polysaccharide A and PD-1 and PD-L1 antibodies in combined treatment of respiratory system tumors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Example 1 Preparation of Bacteroides fragilis ZY-312 zwitterionic capsular polysaccharide

[0068](1) Streak-inoculate Bacteroides fragilis ZY-312 strains on blood plates, culture anaerobically for 48 hours, select a single colony and inoculate it in plant-derived peptone liquid medium for fermentation and culture for 8 hours (at a temperature of 37°C), and the obtained bacteria The solution was centrifuged and precipitated at 3000r / min, centrifuged for 15min, the supernatant was removed, and the precipitate was collected to obtain the Bacteroides fragilis ZY-312 sludge.

[0069] (2) Take 50g of the bacteria slime prepared in step (1), add 300g of purified water to resuspend the bacteria, adjust the pH to 3.5 with 1mol / L hydrochloric acid solution, extract at 100°C for 1.5h, cool to room temperature, and centrifuge at 12000g for 10min at room temperature , take the supernatant to obtain the crude sugar solution;

[0070] (3) The crude sugar solution is concentrated by ...

Embodiment 2

[0074] Example 2 Application of Bacteroides fragilis zwitterionic capsular polysaccharide combined with PD-1 antibody in the treatment of Lewis lung cancer in mice

[0075] 1. Experimental design and process

[0076] In order to verify the therapeutic effect of the Bacteroides fragilis zwitterionic capsular polysaccharide combined with PD-1 antibody provided in Example 1 on non-small cell lung cancer, C57BL / 6 mice were selected for experiments in this example, and the method of transplanted tumor model was used to establish small Mouse non-small cell lung cancer model. Take the tumor cells of the passaged Lewis lung cancer-bearing mice, and dilute the concentration of tumor cells with normal saline to 1×10 7 0.2 mL of the cell suspension per mL was inoculated subcutaneously in the right axilla of the mouse to establish a Lewis lung cancer tumor-bearing mouse model. After successful modeling, the model mice were randomly divided into model group, PD-1 antibody group, PSA-ZY-3...

Embodiment 3

[0107] Example 3 Application of capsular polysaccharide A combined with PD-L1 antibody in the treatment of small cell lung cancer

[0108] 1. Experimental design

[0109] In order to verify the therapeutic effect of the Bacteroides fragilis zwitterionic capsular polysaccharide combined with PD-1 antibody provided in Example 1 on small cell lung cancer, this example uses Trp53 loxP / loxP ;Rb1 loxP / loxP ; Rb12 loxP / loxP Experiments were carried out on mice, and a mouse small cell lung cancer model was established by using the method of xenograft tumor model. With Ad-CreCaPi (Ad-CreCaPi: titer is 10 7 Add 2 μL of PfU Ad-Cre to 246.8 μL of MEM, and then add 1.2 μL of 2mol / L CaCl 2 , purchased from VECTOR B IOLABS) co-precipitates induce Trp53 loxP / loxP ;Rb1 loxP / loxP ; Rb12 loxP / loxP Small cell lung cancer cells (SCLC cells) obtained from mice were adjusted to a concentration of SCLC cells of 1×10 with Matrigel (Matrigel: serum-free medium = 1:1, Matrigel was purchased from ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Weight average molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses application of drug combination of bacteroides fragilis zwitterionic capsular polysaccharide and a PD-1 antibody and / or a PD-L1 antibody in prevention and treatment of respiratory system tumors. A large number of experiments prove that the bacteroides fragilis zwitter-ion capsular polysaccharide, especially the zwitter-ion capsular polysaccharide extracted from bacteroides fragilis ZY-312 with the preservation number of CGMCC No.10685, and the PD-1 antibody / PD-L1 antibody are combined for use, so that the immune cell proportion and the immune factor level can be adjusted, the anti-tumor immune response of a body is enhanced, and the respiratory system tumors are effectively prevented and treated.

Description

technical field [0001] The present invention relates to the field of biomedicine, in particular, the present invention relates to the application of a combination of Bacteroides fragilis zwitterionic capsular polysaccharide and PD-1 antibody / PD-L1 antibody in the treatment of respiratory system tumors. Background technique [0002] Respiratory system neoplasm refers to any disease characterized by anatomically located malignant cells in the respiratory system, including lung cancer, nasopharyngeal cancer, and laryngeal cancer. Clinically common types include non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and nasopharyngeal carcinoma in head and neck squamous cell carcinoma (HNSCC). cancer and laryngeal cancer. [0003] Head and neck squamous cell carcinoma (HNSCC) is the main pathological type of malignant tumors of the head and neck, and its incidence ranks sixth among common malignant tumors, accounting for about 90% of all head and neck tumors. cells...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61K31/715A61P35/00C12P19/26C08B37/00C12R1/01
CPCA61K31/715A61K39/3955A61P35/00C12P19/26C08B37/0003A61K2300/00Y02A50/30
Inventor 邝高波李平周秋云刘洋洋
Owner GUANGZHOU ZHIYI PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com